Uniqure NV (QURE) revenue breakdown

Healthcare · Biotechnology · Market cap $1.2B

By product, License revenues is the largest at 99% of fiscal 2025 revenue, growing 30% a year over 5 years.

Revenue by product

Fiscal years, as Uniqure NV reports them in its 10-K filings; fiscal 2025 total $16M.

Products2016201720182019202020212022202320242025Share
License revenues————$4M$517M$100M$3M$10M$16M 99%
Collaboration revenues————$59,000$7M$5M$2M$11M$164,000 1%
Contract manufacturing revenues——————$2M$11M$6M— —
License revenues from related parties————$33M————— —
Collaboration revenues$7M————————— —
License revenues from related party$4M$4M$8M$5M—————— —
Collaboration revenues—$5M———————— —
Collaboration revenues from related party$13M$4M$4M$2M—————— —
License revenues$975,000————————— —
Collaboration revenues from related parties————$136,000————— —
License revenues—$8,000———————— —
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for QURE.
Open QURE in Investingly

Questions

Where does Uniqure NV make its money?

In fiscal 2025, by product: License revenues $16M, Collaboration revenues $164,000.

From Uniqure NV's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.